Algernon Pharmaceuticals Inc., a clinical stage pharmaceutical development company, focuses in the areas of nonÂ-alcoholic steatohepatitis, liver disease, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury. The company's lead candidate is NP-120, a N-methyl-D-aspartate (NMDA) receptor antagonist, which targets NMDA-type subunit 2B (Glu2NB) and prevents glutamate signalling. Algernon Pharmaceuticals Inc. is headquartered in Vancouver, Canada.
Read More